Corify Care, a Spanish start-up supported by EIT Health, has secured EUR 6M in funding to scale its cutting-edge cardiac mapping technology across Europe.
Since its founding, Corify Care has benefited from the extensive support of EIT Health. From navigating complex regulatory landscapes to securing funding and fostering connections with key stakeholders, EIT's support has been instrumental in Corify’s journey. In 2020, Corify’s technology was recognised as Europe’s most innovative, and in 2022, EIT Health financed the SAVE-COR (ACORYS) project with over EUR 2.5M, enabling pivotal clinical trials involving more than 1,000 patients across Spain and Portugal. This work laid the foundation for Corify Care obtaining the CE Mark under Europe’s rigorous Medical Device Regulation (MDR), achieved in July 2024.
Evidence of Clinical Impact
Cardiac arrhythmias, such as atrial fibrillation (AF), impact millions of lives globally, with potentially severe consequences like strokes and heart failure. In Europe alone, projections suggest that 17.9 million people will suffer from AF by 2060. Yet, existing cardiac mapping methods remain invasive, time-consuming, and uncomfortable for patients.
Corify Care’s ACORYS system offers a groundbreaking alternative. This non-invasive technology utilises 128 body surface sensors to create highly detailed, real-time electroanatomic heart maps without the need for CT scans or MRIs. By streamlining the process, ACORYS empowers clinicians to diagnose arrhythmias accurately and plan procedures like AF ablation and pacemaker implantation with precision and efficiency.
Recent clinical studies underscore the transformative potential of ACORYS. The system demonstrated an 88.9% success rate for patients undergoing AF ablation in comparison to a 48% success rate using traditional approaches outside the pulmonary veins. By offering deeper insights into arrhythmia circuits before catheter insertion, ACORYS not only optimises clinical outcomes but also significantly enhances the patient experience.
A Vision for the Future
The latest EUR 6M includes EUR 3M from a private investment round led by Clave-Mondragón and an additional EUR 3M in public grants. The investment marks a significant step in transforming the diagnosis and treatment of cardiac arrhythmias, a condition that affects millions and is poised to become a major global health challenge.
This milestione funding injection will enable Corify to expand the deployment of ACORYS across Europe and position the company for entry into the U.S. market, with FDA approval expected in the coming months. In parallel, the startup is developing ACORYS 2.0, a next-generation system that integrates digital twins and artificial intelligence to further personalise arrhythmia diagnosis and treatment. These innovations solidify Corify Care’s position as a leader in cardiac health and herald a new era in global cardiac mapping.
EIT Health’s innovation projects and programmes help start-ups like Corify Care to access funding and achieve key milestones which accelerate their journey to market access.
Share this page
